Cargando…

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Front-line treatment for follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len). We conducted a random-effects Bayesian network meta-analysis (NMA) of phase 3 randomized controlled trials (RCTs) to identify the reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yucai, Zhou, Shouhao, Qi, Xinyue, Yang, Fang, Maurer, Matthew J., Habermann, Thomas M., Witzig, Thomas E., Wang, Michael L., Nowakowski, Grzegorz S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728708/ https://www.ncbi.nlm.nih.gov/pubmed/34987165 http://dx.doi.org/10.1038/s41408-021-00598-x

Ejemplares similares

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials
por: Jing, Caixia, et al.
Publicado: (2023)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma
por: Ratnasingam, Sumita, et al.
Publicado: (2019)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
por: Kuwahara-Ota, Saeko, et al.
Publicado: (2018)

Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How
por: Pavanello, Francesca, et al.
Publicado: (2016)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
por: Desai, Sanjal H., et al.
Publicado: (2022)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
por: Chau, I, et al.
Publicado: (2003)

Genetic diversity of newly diagnosed follicular lymphoma
por: Asmann, Y W, et al.
Publicado: (2014)

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
por: Correia, Cristina, et al.
Publicado: (2023)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
por: Tracy, S I, et al.
Publicado: (2017)

P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hwang, Steven, et al.
Publicado: (2023)

P1091: CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA
por: Malafronte, Rosalia, et al.
Publicado: (2023)

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
por: Durot, Carole, et al.
Publicado: (2023)

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
por: Romejko-Jarosinska, Joanna, et al.
Publicado: (2022)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
por: Wang, Yucai, et al.
Publicado: (2019)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
por: Bock, Allison M., et al.
Publicado: (2023)

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma
por: Mondello, Patrizia, et al.
Publicado: (2021)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
por: Cunha, Jéssica Santos, et al.
Publicado: (2021)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

P1110: EFFICACY AND SAFETY OF IMMUNOCHEMOTHERAPY IN TREATMENT OF FOLLICULAR NON-HODGKIN’S LYMPHOMA DURING COVID-19 PANDEMIC: A STUDY OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES
por: Galusic, D., et al.
Publicado: (2022)

History of autoimmune conditions and lymphoma prognosis
por: Kleinstern, Geffen, et al.
Publicado: (2018)

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
por: Yi, Jun Ho
Publicado: (2021)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7124atdqfs8d838c9oq6r16rin